TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the closing of its previously announced registered direct ...
Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systemsTORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ...
Profound Medical Corp. remains rated Sell due to persistent competitive pressures, missed growth promises, and deteriorating financials. PROF's recent 20% stock spike followed news of a Dallas Medical ...
Hosted on MSN
Exclusive: Profound raises $35M as Sequoia backs its ambitious bid to become the Salesforce of AI search
As AI chatbots like ChatGPT and Perplexity reshape how people search—siphoning queries away from Google—startups are racing to help brands stay visible in AI-generated responses. Profound, which ...
Profound Medical has an innovative product, Tulsa Pro, for prostate cancer and BPH, but has struggled with limited revenue growth and unprofitability since FDA approval in 2019. Despite recent revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback